AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
22 sept. 2023 09h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the...
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
11 sept. 2023 13h00 HE
|
AIM ImmunoTech Inc.
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to...
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
15 août 2023 06h45 HE
|
AIM ImmunoTech Inc.
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023 – Company to host conference call and...
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
09 août 2023 09h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss...
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
08 août 2023 08h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a...
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
18 juil. 2023 19h30 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a notice that the Company has learned that unknown person(s) and/or...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
10 juil. 2023 08h05 HE
|
AIM ImmunoTech Inc.
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
14 juin 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
12 juin 2023 08h45 HE
|
AIM ImmunoTech Inc.
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for the...
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
15 mai 2023 08h45 HE
|
AIM ImmunoTech Inc.
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance pancreatic...